☆ 4.2 Review

Efficacy of Eltrombopag with Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone on Severe Aplastic Anaemia: A Systematic Review and Meta-analysis

CLINICAL DRUG INVESTIGATION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Hematology

Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study

Yarong Chi et al.

Summary: This study evaluated the efficacy of avatrombopag in treating patients with secondary aplastic anemia (AA) after chemoradiotherapy. The use of AVA in patients with AA caused by radiotherapy can achieve good clinical response and tolerability. The total cumulative dose of AVA is closely associated with treatment response.

EXPERIMENTAL HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia

Olga Goronkova et al.

Summary: This study compared the efficacy and safety of eltrombopag combined with immunosuppressive therapy and immunosuppressive therapy alone in treatment-naive children with severe and very severe aplastic anemia. The results showed that adding eltrombopag to standard immunosuppressive therapy increased the complete response rate and overall response rate compared to immunosuppressive therapy alone. The greatest benefit from eltrombopag combined with immunosuppressive therapy was observed in patients with severe aplastic anemia, but not in those with very severe aplastic anemia.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Medicine, General & Internal

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

R. Peffault de Latour et al.

Summary: Eltrombopag improves the efficacy of standard immunosuppressive therapy for severe aplastic anemia, leading to higher complete response rates within 3 months.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Hematology

Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag

Yoshitaka Zaimoku et al.

Summary: This study aimed to investigate the relationship between response to immunosuppressive therapy plus eltrombopag and response to immunosuppressive therapy alone in severe aplastic anemia patients. The study found that blood counts remained the best predictors of response to nontransplant therapies in severe aplastic anemia, and the addition of eltrombopag improved treatment response.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Hematology

Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study

Bhavisha A. Patel et al.

Summary: Patients with severe aplastic anemia (SAA) are treated with bone marrow transplant (BMT) or immunosuppression (IST) depending on individual factors. The addition of eltrombopag (EPAG) to standard IST for SAA improves hematologic responses. However, the rates and characteristics of long-term complications, relapse, and clonal evolution with this new regimen are not yet known. This study reports a cumulative relapse rate of 39% in responding patients and a clonal evolution rate of 15% in all treated patients at 4 years. Relapse occurred at distinct timepoints and most relapsed patients responded to retreatment. Clonal evolution to high-risk abnormalities was noted in 5.7% of patients and was associated with poorer overall survival.

BLOOD (2022)

添加到收藏夹

Review Hematology

PNH Clones for Aplastic Anemia with Immunosuppressive Therapy: A Systematic Review and Meta-Analysis

Jingke Tu et al.

Summary: The meta-analysis indicated that PNH clones play an evidence-based role in predicting a better response in AA patients undergoing immunosuppression therapy.

ACTA HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Eltrombopag added to immunosuppression for children with treatment-naive severe aplastic anaemia

Emma M. Groarke et al.

Summary: The study compared pediatric patients under 18 years of age who received EPAG plus standard IST with a historical cohort who received IST alone, indicating that EPAG did not improve outcomes in children with treatment-naive SAA. However, in adults, EPAG significantly improved overall response rate. Younger children had lower response rates compared to adolescents.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Eltrombopag in children with severe aplastic anemia

Harry Lesmana et al.

Summary: This study evaluated the efficacy and safety of standard immunosuppressive therapy and combination therapy with eltrombopag in pediatric severe aplastic anemia patients. The results showed a higher objective response rate in the treatment group with eltrombopag added, and no significant differences in infections between the two therapies.

PEDIATRIC BLOOD & CANCER (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children

Ma Jie et al.

Summary: The study evaluated the efficacy and safety of eltrombopag as a first-line therapy in pediatric patients with aplastic anemia. Results showed significantly increased complete response rates without intolerable side effects compared to historical cohort after 6 months of treatment.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study

Meixin Fang et al.

Summary: The study found that the combination of E-PAG and IST therapy was more effective than IST alone in the treatment of pediatric SAA after 6 months, with good tolerability and compliance.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2021)

添加到收藏夹

Review Surgery

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA 2020 statement, an updated version of the 2009 statement, includes new reporting guidance that reflects advances in research methods. This article introduces the PRISMA 2020 27-item checklist and related information.

INTERNATIONAL JOURNAL OF SURGERY (2021)

添加到收藏夹

Article Hematology

Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study

Jun Ho Jang et al.

Summary: High-dose romiplostim is effective and well tolerated in patients with AA refractory to IST, with the primary efficacy endpoint being an 84% proportion of patients achieving any hematological response at week 27 and a trilineage response of 39% at week 53.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Thomas Winkler et al.

BLOOD (2019)

添加到收藏夹

Review Hematology

Management of aplastic anemia after failure of frontline immunosuppression

Filomena Pierri et al.

EXPERT REVIEW OF HEMATOLOGY (2019)

添加到收藏夹

Meeting Abstract Hematology

Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World

Jinsong Jia et al.

BLOOD (2019)

添加到收藏夹

Letter Biophysics

Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia

Lin-Pierre Zhao et al.

BONE MARROW TRANSPLANTATION (2019)

添加到收藏夹

Review Pharmacology & Pharmacy

Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis

Yaqun Hong et al.

CLINICAL DRUG INVESTIGATION (2019)

添加到收藏夹

Meeting Abstract Hematology

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Emma M. Groarke et al.

BLOOD (2019)

添加到收藏夹

Article Hematology

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia

Nelli Bejanyan et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Review Medicine, General & Internal

Aplastic Anemia

Neal S. Young

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Danielle M. Townsley et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Hematology

Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant

Carlo Dufour et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Eltrombopag: A Review of Its Use in Patients with Severe Aplastic Anaemia

Paul L. McCormack

DRUGS (2015)

添加到收藏夹

Article Hematology

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

Andrea Bacigalupo et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Article Hematology

Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

Andrea Bacigalupo et al.

HAEMATOLOGICA (2015)

添加到收藏夹

Article Hematology

First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy

Nao Yoshida et al.

HAEMATOLOGICA (2014)

添加到收藏夹

Article Hematology

The optimal immunosuppressive therapy for aplastic anemia

Seung Hwan Shin et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

Matthew J. Olnes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Article Hematology

Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia

Phillip Scheinberg et al.

BRITISH JOURNAL OF HAEMATOLOGY (2009)

添加到收藏夹

Article Cell & Tissue Engineering

Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells

Hong Qian et al.

CELL STEM CELL (2007)

添加到收藏夹

Review Hematology

Current concepts in the pathophysiology and treatment of aplastic anemia

Neal S. Young et al.

BLOOD (2006)

添加到收藏夹

Article Hematology

Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia

C Sugimori et al.

BLOOD (2006)

添加到收藏夹

Article Medicine, General & Internal

Antithymocyte globulin and cyclosporine for severe aplastic anemia - Association between hematologic response and long-term outcome

S Rosenfeld et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.